Understanding how GLP‑1 medicines are reshaping the global obesity conversation

The advent of GLP‑1 medicines has ignited unprecedented worldwide media interest across health, policy, business and culture. Over the past 14 months, fast‑moving narratives have made it increasingly challenging for communicators and decision‑makers to maintain a clear, comparative view of what truly drives conversation, scrutiny and momentum.

Our AI-powered and expert‑interpreted analysis of 15,439 English‑language online news articles (published between January 2025 – February 2026) reveals how governments, companies, innovators and cultural voices are shaping the new obesity‑treatment landscape.

What you’ll learn:

– How competition, pricing negotiations and policy debates define the market dynamics of GLP‑1 treatments
– Which companies lead the conversation and how their share of voice compares globally
– How sentiment varies by region and the factors driving positive or negative coverage
– How celebrity influence – from Oprah to TikTok creators – shapes public perception and cultural narratives
– What regional differences reveal about policy priorities, access expectations, and commercial battlegrounds (including Europe and APAC)